The Journal of Rheumatology最新文献

{"title":"Screening Multisystem Inflammatory Syndrome in Children: Accuracy of the American College of Rheumatology Screening Algorithm.","authors":"Greta Mastrangelo,Paul Tsoukas,Trent Mizzi,Beth D Gamulka,Amy Xu,Arthur Hoi Hin Cheng,Rae S M Yeung, ","doi":"10.3899/jrheum.2025-0587","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0587","url":null,"abstract":"OBJECTIVEDiagnosing Multisystem Inflammatory Syndrome in Children (MIS-C) is challenging, as it shares clinical features with other childhood febrile illnesses. In response to the emergence of this syndrome during the pandemic, the American College of Rheumatology (ACR) developed a screening algorithm for the evaluation of MIS-C. We aimed to determine the accuracy of the ACR algorithm in distinguishing patients with MIS-C from other febrile children.METHODSA single-center case-control study was conducted on children with suspected or confirmed MIS-C from March 2020 to March 2022. The cohort was divided into two groups: the MIS-C group, including children with confirmed MIS-C, and febrile controls, consisting of children suspected but ultimately not diagnosed with MIS-C. The ACR MIS-C screening algorithm was retrospectively applied to both groups. The diagnosis obtained was compared with the WHO and CSTE/CDC case definitions. Sensitivity, specificity, and 95% confidence intervals were calculated.RESULTS402 children (241 MIS-C, 161 febrile controls) were included. Median age was 4.2 years, and 58.9% were male. The ACR screening algorithm had 74.3% sensitivity, 99.2% specificity, and 87.0% balanced accuracy when the WHO case definition was used as the gold standard; and 86.2% sensitivity, 95.8% specificity, and 91.0% balanced accuracy when the CSTE/CDC case definition was the gold standard.CONCLUSIONThe ACR MIS-C screening algorithm demonstrates high specificity, accuracy, and good sensitivity in identifying children with MIS-C at the onset of the disease. Despite being developed early in the pandemic with limited data available, the ACR algorithm effectively differentiates children with MIS-C from febrile controls.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Integrin αvβ6 Autoantibodies as a Biomarker for Ulcerative Colitis in Patients With Axial Spondyloarthritis.","authors":"Enoch Yau,Tina Chim,Melissa Lim,Robert D Inman","doi":"10.3899/jrheum.2024-1296","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1296","url":null,"abstract":"OBJECTIVEAnti-integrin αvβ6 autoantibodies (AIA) have recently been described as an informative biomarker for ulcerative colitis (UC), demonstrating a high sensitivity and specificity compared to patients without inflammatory bowel disease (IBD). Given the association between axial spondyloarthritis (AxSpA) and IBD, we sought to evaluate the potential of AIA as a biomarker in AxSpA patients with or without concurrent IBD.METHODSUsing an established ELISA protocol, we measured AIA levels in sera of patients with (i) AxSpA and UC (n=18), (ii) AxSpA and Crohn's Disease (CD) (n=29), (iii) AxSpA alone (n=48), and healthy controls (HC) (n=48). AIA absorbance values were compared between patient groups and clinical variables were compared with AIA positivity.RESULTSPatients with AxSpA and UC showed a significant increase in mean absorbance and AIA positivity rate compared with AxSpA alone. For the diagnosis of UC among AxSpA patients, AIAs had a sensitivity of 55.6% and specificity of 89.6%, and receiver operating characteristic analysis yielded an area under curve value of 0.83. AIA positivity was associated with a family history of IBD in patients with AxSpA and UC. Surprisingly, AIA-positive patients had decreased mean CRP and BASDAI compared with AIA-negative patients. Examining serial samples, we observed that 3 of 10 AIA positive patients became AIA-negative, whereas AIA-negative to AIA-positive transitions were not observed.CONCLUSIONAIA demonstrated potential as a diagnostic test for UC within AxSpA patients, particularly those with a family history of IBD. To our knowledge, this is the first study to date examining AIA in AxSpA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides.","authors":"Carrie Ye,Roko P A Nikolic,May Choi,Aurore Viviane Fifi-Mah,Jeffrey Graham,Liam J O'Neil,Alexandra Kobza,Keith C K Lau,Lourdes Gonzalez Arreola,Jordi Pardo Pardo,Alexandra Ladouceur,Alexandra Saltman,Dirk Velthuizen,Faiza Khokhar,Ines Colmegna,Janet E Pope,Janet Roberts,Marie Hudson,Megan Himmel,Nancy Maltez,Sabrina Hoa,Glen S Hazlewood,Shahin Jamal","doi":"10.3899/jrheum.2025-0481","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0481","url":null,"abstract":"OBJECTIVEImmune checkpoint inhibitors (ICIs) are being increasingly used in patients with preexisting inflammatory arthritides (IAs). However, there are concerns that concomitant baseline immunosuppression at the time of ICI initiation may worsen cancer outcomes, a risk that needs to be balanced with the risk of IA flare. The objective of this study was to develop a living guideline that will offer up-to-date guidance on the management of baseline immunosuppression for preexisting IAs when initiating cancer immunotherapy with ICIs.METHODSThe Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting IAs.RESULTSWe identified 67 relevant publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 44 on preexisting IA. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of IA flare, risk of organ- or life-threatening manifestations, and the potential effect of immunosuppression on cancer outcomes. Four specific recommendations were made, one each for preexisting rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, and spondyloarthritis, considering both the available evidence and expert consensus. The general recommendation for preexisting IAs was to reduce or stop baseline immunosuppression, unless there are extraarticular organ- or life-threatening manifestations.CONCLUSIONThis living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting IA when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites (www.rheum.ca, www.canrio.ca). (PROSPERO registration: CRD42023461024).","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases.","authors":"Carrie Ye,Roko P A Nikolic,May Choi,Aurore Viviane Fifi-Mah,Jeffrey Graham,Liam J O'Neil,Alexandra Kobza,Keith C K Lau,Lourdes Gonzalez Arreola,Jordi Pardo Pardo,Alexandra Ladouceur,Alexandra Saltman,Dirk Velthuizen,Faiza Khokhar,Ines Colmegna,Janet E Pope,Janet Roberts,Marie Hudson,Megan Himmel,Nancy Maltez,Sabrina Hoa,Glen S Hazlewood,Shahin Jamal","doi":"10.3899/jrheum.2025-0482","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0482","url":null,"abstract":"OBJECTIVEAlthough immune checkpoint inhibitors (ICIs) are increasingly used in patients with preexisting systemic autoimmune rheumatic diseases (SARDs), a key concern is whether baseline immunosuppression at the start of ICI treatment might negatively affect cancer outcomes. This risk must be carefully weighed against the potential for a SARD flare. The objective of this study was to develop a living guideline that will provide up-to-date guidance on the management of baseline immunosuppression for preexisting SARDs when initiating cancer immunotherapy with ICIs.METHODSThe Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting SARDs.RESULTSWe identified 67 publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 36 on preexisting SARD. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of SARD flare, risk of organ- or life-threatening manifestations, and potential effect of immunosuppression on cancer outcomes. Seven specific recommendations were made, 1 each for preexisting systemic lupus erythematosus, systemic sclerosis, Sjögren disease, myositis, sarcoidosis, vasculitis, and Behçet disease, considering both the available evidence and expert consensus. The general recommendation for preexisting SARDs was to continue baseline immunosuppression, particularly if there are organ- or life-threatening manifestations.CONCLUSIONThis living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites (www.rheum.ca, www.canrio.ca). (PROSPERO registration: CRD42023461024).","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a Practical Approach to Diagnosis of Sjögren's Disease in Clinical Practice.","authors":"Nirmay Shah,Arthur A M Bookman","doi":"10.3899/jrheum.2025-0574","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0574","url":null,"abstract":"OBJECTIVEThe 2016 ACR-EULAR Classification Criteria (AECC) borrow from oral pathology, ophthalmology, pathology and serology to define Sjogren's disease (SD). The objective of this study is to analyze the utility of incorporating the 2016 AECC tools into clinical practice.METHODSA cross-sectional database with 374 patients evaluated on protocol between 1993 and 2019 at the University Health Network Multidisciplinary Sjögren's Clinic was used for the purpose of this data analysis. All patients used for this analysis had a complete evaluation including serology, ocular surface staining and minor salivary gland (MSG) biopsy.RESULTSOf the 374 patients, 263 (70.3%) were diagnosed with SD in clinic on the basis of Schirmer's Test (ST), Unstimulated Salivary Flow (USSF) and serology results alone (Group A). An additional 14% were diagnosed after further assessment with ocular surface staining (Ophthalmology) and minor salivary gland biopsy (ENT) (Group B). Group C patients did not have SD. Groups B and C together were frequently seronegative (for ANA and/or anti-Ro) or AMA positive. Seronegative patients with abnormal ST and USSF had a positive MSG biopsy in 70% of cases.CONCLUSIONSD could be diagnosed according to 2016 AECC in most patients on the basis of ST, USSF and serology results where there is concern for the disease on clinical evaluation. Patients that required further testing for diagnosis had some distinctive features. This analysis provides the practicing physician with some guidelines for establishing a diagnosis of SD in clinic.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to Manage Cardiovascular Disease in Psoriatic Disease: Evidence and Time Management in Clinic.","authors":"Maria-Angeliki Gkini,Pamela Diaz,Cheryl F Rosen,Claudia Goldenstein-Schainberg","doi":"10.3899/jrheum.2025-0811","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0811","url":null,"abstract":"Early recognition and appropriate management of cardiovascular (CV) disease (CVD) in patients with psoriatic disease (PsD) is critical for prevention of early morbidity and mortality. PsD and CVD share common pathogenic mechanisms, including upregulation of proinflammatory cytokines like tumor necrosis factor. Potential CV comorbidities should be assessed in all patients with PsD through clinical history, risk factor assessment (eg, diabetes, hypertension, dyslipidemia), blood tests, and imaging, when required. Collaboration with the patient's primary care physician is essential, offering preventive measures such as healthy lifestyle advice (eg, diet, exercise, weight loss, smoking and drinking cessation). Management of comorbid conditions requires a multidisciplinary setting of family doctors, internists, cardiologists, dermatologists, and rheumatologists. Treating psoriatic arthritis and psoriasis to remission is recommended; however, the data on CVD risk modification remain inconclusive, necessitating further studies. Thus, routine CVD assessment and management should be provided to patients with PsD, despite practical difficulties such as clinical time constraints and lack of support staff. The evidence and experiences of a dermatologist and rheumatologist assessing and managing CVD in clinic were presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of giant cell arteritis-associated visual outcomes at a tertiary hospital in Ontario, Canada.","authors":"Mats L Junek,Rahul Chanchlani,Amadeo R Rodriguez,Nader Khalidi,Amber O Molnar","doi":"10.3899/jrheum.2025-0459","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0459","url":null,"abstract":"OBJECTIVEThere are limited data concerning outcomes in those with giant cell arteritis-associated vision changes (GCA, GCAVCs). We estimated the association of intravenous, compared to oral, glucocorticoids with outcomes in GCAVCs.METHODSWe conducted a retrospective cohort study at a tertiary healthcare facility in Ontario, Canada. Individuals aged 50 years or older with an international classification of disease version 10 (ICD-10) diagnostic code for GCA associated with a healthcare visit between November 2017 to December 2023 were identified for inclusion. Diagnoses of GCA were verified as the final diagnosis of the treating clinician and were required to be supported by histologic, radiographic, and/or biochemical evidence of inflammatory vasculopathy. GCAVCs were identified by clinical assessments. Treatment exposures were defined as whether the individual was first exposed to intravenous or oral glucocorticoids. The primary outcome was reported visual improvement after treatment. We used logistic regression to estimate treatment effects adjusting for demographic and disease factors.RESULTSIn 289 individuals with GCA, 77 (26.6%) had GCAVCs. 70.1% of GCAVCs led to permanent vision loss and visual recovery was seen in 16.0% of participants. We found no difference in outcomes for those first treated with intravenous versus oral glucocorticoids (adjusted odds ratios 0.43-1.72, 95% confidence interval range 0.02-123.68).CONCLUSIONGCAVCs are common and frequently associated with permanent vision loss. While the precision of our results was limited by sample size, we did not find evidence that IV before oral glucocorticoids was associated with visual improvement in GCAVCs.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery and Clinical Validation of C1M and C4M as Soluble Biomarkers for Diagnosis, Prognosis, and Symptom Prediction in Psoriatic Disease and Other Inflammatory Arthropathies.","authors":"Maria-Angeliki Gkini,Wilson Liao,Kurt de Vlam,Vinod Chandran,Signe Holm Nielsen","doi":"10.3899/jrheum.2025-0671","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0671","url":null,"abstract":"Psoriatic disease (PsD) is a complex, heterogeneous disease with unmet medical needs in terms of its diagnosis, management, and prognosis. The identification of biomarkers could improve the implementation of precision medicine in PsD, but to date, none of these biomarkers have been clinically validated. Biomarkers can support clinical trials in several ways, including (1) diagnostics, (2) drug pharmacodynamics, (3) prognostics for patient selection and monitoring of drug efficacy, and (4) predictive models for clinical outcomes. Biomarkers can sometimes be used for both diagnosis and prognosis. Benefits of biomarkers use may include shorter duration of clinical trials, faster access to new treatments, and a personalized approach to disease management. Several potential biomarkers have recently demonstrated promise for use in PsD, including C1M, a serum biomarker reflecting collagen type I collagen degradation, and C4M, a type IV collagen metabolite, but clinical validation has not yet been completed. Here, and as presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2024 annual meeting, we summarize the status of biomarker discovery for PsD and their overlap with other musculoskeletal diseases such as rheumatoid arthritis and axial spondyloarthritis.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare and Severe Cutaneous Presentation of Systemic Lupus Erythematosus.","authors":"Katharina W Horn,Alyssa Breneman,Amir Reza Djavid,Alexis D Boneparth,Laura E Levin","doi":"10.3899/jrheum.2025-0367","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0367","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual and Socio-ecological Resilience in Childhood-Onset Systemic Lupus Erythematosus: Associations with Patient Characteristics and Psychosocial Patient-Reported Outcomes.","authors":"Isabella Zaffino,Louise Boulard,Joanna Law,Ashley Danguecan,Asha Jeyanathan,Lawrence Ng,Sandra Williams-Reid,Kiah Reid,Angela Cortes,Eugene Cortes,Deborah M Levy,Linda T Hiraki,Andrea M Knight","doi":"10.3899/jrheum.2025-0375","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0375","url":null,"abstract":"OBJECTIVEThis study investigates individual and socio-ecological resilience and their relationship with sociodemographic and disease characteristics, and psychosocial patient-reported outcomes in childhood-onset systemic lupus erythematosus (cSLE).METHODSWe conducted a cross-sectional study of patients with cSLE ages 11-22 years at a Canadian tertiary center from October 2021-July 2024. The Connor-Davidson Resilience Scale (CD-RISC 10) assessed individual resilience. The Child and Youth Resilience Measure-Revised (CYRM-R) assessed socio-ecological resilience. Linear regression models examined associations between resilience with socio-demographic (e.g., health literacy, adverse childhood experiences (ACEs)) and disease factors (e.g., age of onset, duration, disease activity). Pearson correlations determined relationships between resilience and patient-reported depressive and anxiety symptoms, executive functioning, pain interference and fatigue.RESULTSOf 49 participants, mean scores for individual psychological resilience were CD-RISC 10 of 26.0 (SD=7.1) and socio-ecological resilience were CYRM-R of 73.4 (SD=9.1). Higher resilience on CD-RISC 10 (b=0.99, 95%CI [0.45 to 1.55], p<0.01) and CYRM-R (b=0.84, 95%CI [0.13 to 1.55], p=0.02) was associated with better health literacy on the communication subscale. Lower CYRM-R scores were associated with higher number of ACEs (b=-1.02, 95% CI [-1.88 to -0.17], p=0.02). For patient-reported outcomes, lower scores for both individual and socio-ecological resilience correlated with worse depressive symptoms (r=-0.44, p=0.003 for CD-RISC 10; r=-0.55, p=0.001 for CYRM-R) and executive functioning (r=-0.49, p=0.002 for CD-RISC 10; r=-0.56, p=0.002 for CYRM-R).CONCLUSIONGreater resilience was associated with fewer ACEs, and better health-related communication, patient-reported mental health and executive functioning. Findings highlight the importance of fostering resilience to improve outcomes in youth with cSLE.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}